1. Home
  2. FSBC vs OMER Comparison

FSBC vs OMER Comparison

Compare FSBC & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Five Star Bancorp

FSBC

Five Star Bancorp

HOLD

Current Price

$37.78

Market Cap

741.2M

Sector

Finance

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$9.70

Market Cap

628.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FSBC
OMER
Founded
2002
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
741.2M
628.9M
IPO Year
2021
2009

Fundamental Metrics

Financial Performance
Metric
FSBC
OMER
Price
$37.78
$9.70
Analyst Decision
Buy
Strong Buy
Analyst Count
6
5
Target Price
$37.83
$27.50
AVG Volume (30 Days)
58.0K
1.7M
Earning Date
01-26-2026
11-13-2025
Dividend Yield
2.15%
N/A
EPS Growth
19.76
N/A
EPS
2.70
N/A
Revenue
$141,930,000.00
N/A
Revenue This Year
$34.35
N/A
Revenue Next Year
$17.79
N/A
P/E Ratio
$13.82
N/A
Revenue Growth
25.41
N/A
52 Week Low
$22.22
$2.95
52 Week High
$37.74
$13.60

Technical Indicators

Market Signals
Indicator
FSBC
OMER
Relative Strength Index (RSI) 68.34 52.71
Support Level $34.49 $9.31
Resistance Level $35.48 $11.71
Average True Range (ATR) 1.04 0.64
MACD 0.32 -0.11
Stochastic Oscillator 94.21 15.45

Price Performance

Historical Comparison
FSBC
OMER

About FSBC Five Star Bancorp

Five Star Bancorp is a bank holding company through its subsidiary it operates in California state-chartered non-member bank. The Company provides a broad range of banking products and services to small and medium-sized businesses, professionals, and individuals. It offers loan products like commercial real estate loans, commercial loans, commercial land and construction loans, and farmland loans and offers deposit products like checking accounts, savings accounts, money market accounts, and term certificate accounts. The group has one reportable operating segment; Banking.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: